Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2368460 | 0.85 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL2368426 | 0.85 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL2368706 | 0.85 | RAB9A (0.97) | RAB9ANPC1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2251842 | 0.82 | SIRT5 (1.00) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL3784826 | 0.77 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL30091917 | 0.76 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL2369310 | 0.75 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL18954484 | 0.73 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2GAAHTT | |
| SCHEMBL2369006 | 0.72 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3979882 | 0.72 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | RAB9A 1622/4885NPC1 125/4885SMN1; SMN2 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.